Study of XL820 in Adults With Solid Tumors | NCT00129571

Studies
Study of XL820 in Adults With Solid Tumors

NCT00129571

Sponsor

Exelixis

Status

Completed

Last Update Posted

Jun 4, 2008Estimated

Enrollment

Not provided

Phase

Phase 1

Conditions

Cancer

Interventions

XL820

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jun 2008

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Not provided

Start Date

Aug 2005

Primary Completion Date

Not provided

Completion Date

Not provided

First Submitted Date

Aug 10, 2005

First Submission Date that Met QC Criteria

Aug 10, 2005

First Posted Date

Aug 12, 2005Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jun 2, 2008

Last Update Posted Date

Jun 4, 2008Estimated

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

Not provided

Name	Type	Description	Arm Group Labels	Other Names
XL820	Drug

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Advanced solid tumor
Cancer for which standard therapies do not exist or are no longer effective
Life expectancy of > 3 months
Adequate bone marrow, liver, and kidney function
Willing to use accepted method of contraception during the course of the study
Negative pregnancy test (females)
Written informed consent

Exclusion Criteria:

Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
Investigational drug within 30 days of the start of treatment
Subjects with known brain metastasis
Uncontrolled medical disorder such as infection or cardiovascular disease
Subjects known to be HIV positive
Pregnant or breastfeeding women

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
The Cancer Institute of New Jersey		New Brunswick	New Jersey	08901	United States
Cancer Therapy and Research Center